{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:33:35Z","timestamp":1784691215606,"version":"3.55.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.parkreldis.2019.02.010","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:02:50Z","timestamp":1550793770000},"page":"169-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Creativity related to dopaminergic treatment: A multicenter study"],"prefix":"10.1016","volume":"63","author":[{"given":"Pedro J.","family":"Garcia-Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Martinez Castrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6663-395X","authenticated-orcid":false,"given":"Lydia Vela","family":"Desojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2019.02.010_bib1","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/1531-8257(200009)15:5<869::AID-MDS1016>3.0.CO;2-I","article-title":"Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?","volume":"15","author":"Molina","year":"2000","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2019.02.010_bib2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.parkreldis.2019.02.010_bib3","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/WCO.0b013e3283489687","article-title":"Impulse control disorders in Parkinson's disease: recent advances","volume":"24","author":"Voon","year":"2010","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.parkreldis.2019.02.010_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/mds.26016","article-title":"Clinical spectrum of impulse control disorders in Parkinson's disease","volume":"30","author":"Weintraub","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2019.02.010_bib5","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archneur.63.7.969","article-title":"Association of dopamine agonist use with impulse control disorders in Parkinson disease","volume":"63","author":"Weintraub","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.parkreldis.2019.02.010_bib6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/WNF.0b013e31826e6e6d","article-title":"Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease","volume":"35","author":"Perez-Lloret","year":"2012","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2019.02.010_bib7","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/jnnp-2013-306787","article-title":"Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study","volume":"85","author":"Garcia-Ruiz","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2019.02.010_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2014.5262","article-title":"Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs","volume":"174","author":"Moore","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.parkreldis.2019.02.010_bib9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jns.2016.07.003","article-title":"The high prevalence of impulse control behaviors in patients with early-onset Parkinson's disease: a cross-sectional multicenter study","volume":"368","author":"Vela","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2019.02.010_bib10","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s00415-009-5001-1","article-title":"Changes in artistic style and behaviour in Parkinson's disease: dopamine and creativity","volume":"256","author":"Kulisevsky","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2019.02.010_bib11","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1468-1331.2011.03546.x","article-title":"Artistic productivity and creative thinking in Parkinson's disease","volume":"19","author":"Canesi","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.parkreldis.2019.02.010_bib12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1037\/a0031052","article-title":"The awakening of artistic creativity and Parkinson's disease","volume":"127","author":"Inzelberg","year":"2013","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.parkreldis.2019.02.010_bib13","first-page":"55","article-title":"Dopamine and the biology of creativity: lessons from Parkinson's disease","volume":"5","author":"Lhomm\u00e9e","year":"2014","journal-title":"Front. Neurol."},{"key":"10.1016\/j.parkreldis.2019.02.010_bib14","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/ana.24181","article-title":"Enhanced creative thinking under dopaminergic therapy in Parkinson disease","volume":"75","author":"Faust-Socher","year":"2014","journal-title":"Ann. Neurol."},{"issue":"11","key":"10.1016\/j.parkreldis.2019.02.010_bib15","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.neurol.2009.06.003","article-title":"Groupe \u00e9valuation comportementale de la maladie de Parkinson. [Assessment of hyper- and hypodopaminergic behaviors in Parkinson's disease]","volume":"165","author":"Ardouin","year":"2009","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.parkreldis.2019.02.010_bib16","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/mds.26223","article-title":"International validation of a behavioral scale in Parkinson's disease without dementia","volume":"30","author":"Rieu","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2019.02.010_bib17","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/mds.26587","article-title":"Emotional manifestations of Parkinson disease: neurobiological basis","volume":"31","author":"Castrioto","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2019.02.010_bib18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/syn.21805","article-title":"Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors","volume":"69","author":"Seeman","year":"2015","journal-title":"Synapse"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802019300562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802019300562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:16:01Z","timestamp":1761178561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802019300562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":18,"alternative-id":["S1353802019300562"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2019.02.010","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Creativity related to dopaminergic treatment: A multicenter study","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2019.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}